Hiraoka A, Masaoka T, Nagai K, Kakishita E, Oshiba S, Kageyama T, Okuda K, Tatsumi N, Uchino H, Matsuzawa Y
Center for Adult Diseases, Osaka.
Gan To Kagaku Ryoho. 1993 Sep;20(12):1835-41.
The efficacy and safety of oral granisetron against nausea and vomiting induced by chemotherapy for tumors in the hematopoietic organs were investigated. Depending on the day of anticancer drug administration, single administration or 2 to 6-day repeated administration of granisetron at 2 mg once daily was conducted. The clinical efficacy rate against nausea and vomiting was 91.6% on the first day of administration of anti-cancer drugs and 90% or over on and after the second day of administration. Compared with the status at the previous chemotherapy, a significant decrease in vomiting frequency was observed during the present trial. Adverse events which were suspected to be related to granisetron included 1 case of mild feeling of residual urine and another demonstrating very mild eosinophilia. From the above results, it was confirmed that granisetron was a safe and effective antiemetic against nausea and vomiting induced by anticancer drug administration.
研究了口服格拉司琼对造血器官肿瘤化疗所致恶心和呕吐的疗效及安全性。根据抗癌药物给药日，每日一次给予2mg格拉司琼进行单次给药或2至6日重复给药。抗癌药物给药第一天对恶心和呕吐的临床有效率为91.6%，给药第二天及以后为90%及以上。与上次化疗时的情况相比，本次试验期间呕吐频率显著降低。疑似与格拉司琼相关的不良事件包括1例轻度残余尿感和另一例表现为非常轻度的嗜酸性粒细胞增多。从上述结果证实，格拉司琼是一种安全有效的抗恶心和呕吐药物，可用于对抗抗癌药物给药所致的恶心和呕吐。
